Dear Colleagues,  
Dear Friends,

We have the pleasure to inform you that Amgen and UCB, companies jointly marketing Romosozumab for the treatment of osteoporosis, have now joined the ESCEO-IOF Pre-Competitive Consortium on Osteoporosis and Bone Health (PRECCO). This Consortium, created to support the five-year partnership signed between ESCEO and the World Health Organization to improve the management of osteoporosis, involves a diverse range of stakeholders, who place the osteoporotic patients at the center of their priorities, independently of their immediate strategy, in terms of content and timeline. Both ESCEO and IOF are very proud to welcome two more stakeholders, within this group of partners, dedicating their efforts to the well-being of osteoporotic patients.

With the addition of Amgen and UCB, the PRECCO counts now 25 partners, active in the screening, diagnosis, prevention, treatment and monitoring of osteoporosis.

ESCEO and IOF are very proud of this partnership that will bring osteoporosis as a first priority on the WHO agenda

Best regards,

Jean-Yves Reginster  
President ESCEO